Lymphocyte activation with localized pGL1-TNF-alpha gene therapy in a glioma model.
The major goal of this study was to evaluate the effects of tumor necrosis factor-alpha (TNF-alpha), delivered as pGL1-TNF-alpha, on hematological variables, as well as C6 tumor growth in athymic mice treated with and without radiation. pGL1-TNF-alpha was administered intratumorally at low to high doses (15, 150 and 450 microg) in all three phases of this study. In phase A, pGL1-TNF-alpha expression within tumors was dose dependent and transient, with highest levels seen at 18 h after injection, whereas no TNF-alpha protein was detected in plasma. Low erythrocyte counts, hemoglobin, and hematocrit were associated with tumor presence, but the reduction in these variables was most striking in the group receiving 450 microg of pGL1-TNF-alpha, the group that also exhibited thrombocytopenia at 72 h. In phase B, treatment with pGL1-TNF-alpha at 15 or 150 microg resulted in the greatest degree of splenomegaly, increased spontaneous blastogenesis by splenocytes, and high leukocyte and lymphocyte numbers in the spleen. In these same two groups, flow cytometry analyses of spleen cells showed that high levels of natural killer (panNK+) cells, B (CD19+) lymphocytes, and cells expressing the CD71 and CD25 activation markers were present (p < 0.05). An enhancing effect was also noted in some of the measurements with parental plasmid p WS4 and tumor presence. In phase C, the slowest tumor progression was observed in the groups receiving 15 and 150 microg pGL1-TNF-alpha together with radiation; tumor volumes were 51 and 43% smaller, respectively, than for PBS-injected controls by the end of the study. Collectively, these results show that localized treatment with pGL1-TNF-alpha is hematologically nontoxic at low doses and support the premise that activation of lymphocytes may contribute to the antitumor effects of radiation against a highly aggressive brain tumor.
Gridley
Daila S
DS
Department of Radiation Medicine, Radiobiology Program, Loma Linda University and Medical Center, Loma Linda, CA 92354, USA. dgridley@dominion.llumc.edu
Li
Jun
J
Kajioka
Eric H
EH
Dutta-Roy
Radha
R
Andres
Melba L
ML
Timiryasova
Tatyana M
TM
Fodor
Istvan
I
D000818:Animals; D001835:Body Weight; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D018450:Disease Progression; D005434:Flow Cytometry; D005910:Glioma / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008934:Mitogens / Q000494:pharmacology; D009929:Organ Size; D010957:Plasmids / Q000235:genetics; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use*
D008934:Mitogens; D014409:Tumor Necrosis Factor-alpha